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On November fourth and ﬁfth 2010 a group of more than 100 international investigators gathered in
Atlanta for the second Osteoarthritis (OA) Biomarkers Global Initiative workshop titled “Genetics and
Genomics: New Targets in OA”. The ﬁrst workshop took place in April 2009 and focused on in vitro
(soluble) biomarkers whilst the third and ﬁnal workshop will take place in 2012 and will focus on
imaging biomarkers. The OA Research Society International (OARSI) has organized the workshops. In
addition to OARSI, the National Institute of Arthritis, Musculoskeletal and Skin Diseases, the Arthritis
Foundation, Amgen, Genzyme, the American Orthopaedic Society for Sports Medicine and Pﬁzer spon-
sored the second meeting. It was clear from this meeting that experiments in the genetics, epigenetics
and genomics of OA, are yielding valuable insights into the etiology of this heterogeneous disease but
that much still needs to be learnt. Combining genetic insights with conventional biomarkers and imaging
modalities may provide scientists with the enhanced tools to understand this complex disease. With
those tools in hand, clinicians and industry can develop protocols to ultimately improve patient care.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Osteoarthritis (OA) and the need for novel biomarkers
Over the last 20 years OA has come to be recognized as
a complex disease involving most, if not all, tissues of the joint. OA
has a major heritable component, conﬁrmed by epidemiological
studies and now by molecular investigations. No disease modifying
therapies have yet been developed, severely hampering disease
management. Furthermore, OA is still principally diagnosed once
radiographic changes in joint tissues are detected, often reﬂecting
irreversible damage.
Like most common, complex diseases, the genetic architecture
of OA remains to be clariﬁed. Molecular studies have, however,to: J. Loughlin, Newcastle
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s Research Society International. Pgenerated promising information about the genetic underpinnings;
such novel insights may provide useful information on how the
disease begins and progresses. Moreover, determining pre-clinical
changes or abnormalities that reveal the disease closer to its
starting point could be accomplished at the molecular level with
biomarkers. Strategies are required to detect and intervene early in
the course of OA and to monitor disease progression after treat-
ment. Ultimately these strategies will help scientists understand
the differences between diseased and normal joint tissues and thus
satisfy the needs of clinicians, industry, and patients. The Osteoar-
thritis Research Society International (OARSI) OA Biomarker Global
Initiative aims to help develop such biomarkers through a series of
workshops designed to encourage international participation on
a selection of relevant topics.
The OARSI OA Biomarker Global Initiative
In 2009 funding for a series of three workshops was awarded to
the OA Biomarker Global Initiative by the National Institute of
Arthritis, Musculoskeletal and Skin Diseases (NIAMS). These
meetings provide a forum for interchange of information and ideas
among members of the OA biomarker community by providingublished by Elsevier Ltd. All rights reserved.
I. Meulenbelt et al. / Osteoarthritis and Cartilage 19 (2011) 1091e10941092structure for biomarker discovery and use; providing resources to
move the ﬁeld forward; providing white papers, guidelines, and
validation for use in the ﬁeld; and maintaining momentum in this
critical area. The ﬁrst workshop entitled “Biochemical Biomarker:
Biology, Validation and Clinical Studies” was held in April 2009 in
Bethesda, Maryland. Attendees focused on biochemical biomarkers
of OA1.
Since the ﬁrst workshop, the Global Initiative deﬁned the kind of
partnerships needed by investigators and funding organizations.
The group also developed guidelines for sample collection, devel-
oped a website for sharing information, and began an initiative
between the United States Food and Drug Administration (FDA) and
OARSI. From this latter initiative came guidelines for changes in the
structure for FDA clinical studies. Guidance related to the OA ﬁeld in
general includes biomarker quantiﬁcation; unmet needs in the
biomarker ﬁeld; and information on patient research.
The second workshop
In November 2010 over 100 delegates from across the globe
gathered in Atlanta for the second OARSI biomarkers workshop
titled, “Genetics and Genomics: New Targets in OA”. In addition to
NIAMS, the Arthritis Foundation, Amgen, Genzyme, the American
Orthopaedic Society for Sports Medicine, and Pﬁzer sponsored the
meeting. The workshop focused on current research in genetic,
epigenetic, and genomic studies of OA. Sessions assessed whether
biomarkers derived from these approaches can realistically be used
now or in the near future to identify and monitor people who are at
increased risk for OA, or even to identify those with enhanced
protection from the disease.
Cohort studies
Ongoing debate has centred on how best to select cases for OA
genetic studies. Because OA is a heterogeneous disease, more
reﬁned clinical phenotyping may help stratify the disease into
homogeneous genetic and environmental subsets, thereby
enhancing power of such genetic studies. Such subsets are perhaps
not resolvable until unambiguous association data emerges that
allows the identiﬁcation of the phenotypes of carriers of risk DNA
variant alleles.
The workshop therefore started with a discussion on current
issues regarding case selection. In the ﬁrst OARSI biomarkers
workshop on biochemical markers, the anterior cruciate ligament
(ACL) injury model was proposed to track the onset of OA since it
provides a clear starting point from which to monitor events and
progression to pre-radiographic and radiographic OA. For example,
reﬁned reconstruction techniques for ACL tears allow athletes to
return to the playing ﬁeld. However, 10 years post-surgery, X-rays
show evidence of arthritis in only some individuals, suggesting
mechanical factors alone cannot account for OA. Such studies may
reveal, in a reasonable timeframe, who is most at risk for devel-
oping joint pathology and progression to OA and whether genetic
factors play a modifying role.
In a preliminary study of West Point cadets with and without
ACL injury in the pre- and post-clinical state, commercially avail-
able biomarkers of cartilage degradation and synthesis were
measured. This unique cohort study was possible due to serial
collections, since 1985, of medical and physical activity data from
cadets, beginning at recruitment. Furthermore, ACL tears occur in
this population at approximately 45 per 1,000. Perhaps most
signiﬁcant was the difference in pre-clinical levels of both CPII and
C2C in the ACL injured group as compared to controls, indicating
that characteristics of joint metabolism may predispose, when
physically challenged, to such an ACL injury.Finally, a study was presented that compared serum and syno-
vial ﬂuid biomarkers in the ﬁrst several weeks after acute trauma to
the ACL. In this pilot study, a large panel of biomarkers was
analyzed following injury and treatment with intra-articular
IL-1Ra. Data showed high initial levels of inﬂammatory proteo-
glycans and other matrix molecules followed by delayed collagen
release. Perhaps indicating that early pro-inﬂammatory response to
injury leaves a crucial impact on long-term health consequences of
the joint integrity. As collagen loss is considered irreversible very
early treatment with agents to reduce collagen loss may be
necessary to prevent the onset of post-traumatic OA2.
Candidate genes and genome-wide association scans (GWAS)
Candidate gene and GWAS aim to provide insights into genes
that may confer genetic risk or protection from OA. Thus far, OA
appears to be highly polygenic with multiple risk alleles conferring
small effects. Finding loci under these conditions require large
sample sizes. Current large-scale consortia such as arcOGEN and
TREATwOA are converging towards robust new OA targets with
genome-wide signiﬁcance (P< 108).
Genetic studies in OA have so far provided only a handful of
robust signals, such as single nucleotide polymorphisms (SNPs) at
7q223,4, DIO25 and GDF56,7. Two of these are known to have some
effect on the skeleton. DIO2, a selenoprotein that converts intra-
cellular inactive thyroid hormone to its active form, regulates the
growthplate through thyroidhormone.GDF5, amemberof the TGFb
superfamily of signallingmolecules, is involved in the development,
maintenance, and repair of bone and cartilage. Additional functional
studies are necessary to elucidate the underlying molecular path-
ways,whichmayprovide clues onpossible druggable targets and/or
biomarkers that allow early pre-clinical diagnosis of disease in
carriers of these risk alleles8,9. Gene markers used to predict the
trajectory of OA don’t necessarily have to be polymorphisms. A
session describing the role of epigenetics in common disease
provided insights into how differences in epigenetic proﬁles of
genes encoding proteinases, interleukins and growth factors may
inﬂuence OA progression. Overall differences in gene expression or
epigenetic proﬁles could be useful markers or diagnostic tools.
More candidate genes and polymorphisms are expected as
ongoing GWAS studies reach completion10. Each gene can poten-
tially confer allelic heterogeneity (common and rare pathogenic
variants), with rare genetic variants potentially having stronger and
possibly distinctive effects on phenotype, and therefore offering
greater potential for intervention. Identifying robust polymorphisms
associatedwithOAwon’t provide a complete story.Many SNPs likely
reside outside genes, may not be disease speciﬁc, nor be relevant to
transcripts expressed in joints. Also, associated SNPs may reside
inside genes whose function is not yet understood. Thus, functional
studies are critical. Functional genomic pipelines will elucidate
molecular pathways underlying OA etiology and thus facilitate the
discoveryof therapeutic targets. Functional genomic approacheswill
also provide insight into the molecular background of these OA
susceptibility loci andhopefully uncoverdiseasemechanisms. Lastly,
genetic contributions to the formation of joint shape may add to
information provided by functional genetic approaches.
Challenges (the next step forward)
Data presented at the workshop showed progress in robust
candidate genes, such as GDF5, and reinforced the need to under-
stand the complex interplay between genetic and environmental
causes of OA. To date, too few signals reach genome-wide signiﬁ-
cance whilst even fewer show compelling association across ethnic
groups. Current OA susceptibility alleles are also not providing
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factors such as age, gender and body mass index (BMI). The eluci-
dation of underlying pathways can supply such information as will
collecting more data relevant to genetics, clinical features, and
environmental risk factors. These new data will allow for complete
analyses of OA associated genetic variants.
The ﬁeld of complex trait genetics is moving towards deter-
mining the role of low frequency and rare variants. The 1,000
Genomes Project11 and the UK10K Project can provide OA studies
with additional DNA variants to test whilst the emphasis must
remain on large sample sizes to allow study replication and to also
provide stratiﬁed analyses to both increase and specify attributable
risk. Such second generation sequencing efforts aim to uncover rare
genetic changes in tens of thousands of people across the globe.
Challenges remain in many areas; such as geneeenvironment
interactions that are rarely captured in gene association studies and
which complicate clinical utility. Furthermore, a large part of
heritability remains unexplained. Deep sequencing (whole
genome, exome, and RNA-sequencing) may uncover additional rare
genetic variation speciﬁc to OA susceptibility and may ﬁll-in some
of the heritability gap. Also, biochemical markers or markers that
denote joint shape are needed to provide quantitative phenotyping
for genome-wide analyses of OA endophenotypes.
As the ﬁeld moves towards sequence-based studies across the
whole genome, a better idea of the full spectrum of genetic variants
underlying OA may provide a therapeutic path for early interven-
tion. Microarray expression proﬁles in cartilage have already
provided insight into OA pathophysiology12,13 whilst proteomic
studies may provide insight into biomarkers with a synovial or
cartilage origin14. The inaccessibility of joint tissue and the inva-
siveness of drawing synovial ﬂuid, however, limits their use as
routine biomarkers for OA unless they are released into urine or
blood. Expression proﬁles in blood may provide an accessible new
source of sensitive genomic biomarkers so long as what is occurring
in the damaged joint is reasonably mirrored in blood cells or serum.
A similar conundrum applies to epigenetic analyses e what is the
correct tissue/s and time point in disease development to target?
Future genetic and genomic approaches will need to address
disease heterogeneity; small effect sizes (odds ratios< 1.2); rare
variants of possible large-effects; and epistatic and epigenetic
effects. Functional studies will need to be performed on robust and
replicated signals.
Lastly, the question of combiningmultiple markers to assign risk
for a single individual needs to be addressed. Markers that might be
combined include a single risk entity (e.g., SNP), haplotypes for
multiple variations in a single gene, pathways for multiple
expressed genes, metabolites, and proteins. The challenge will
occur whenmultiple markers cannot be “easily” adapted to provide
an overall indicator of disease risk.
To meet all challenges put forth in Atlanta, the Global Initiative
will establish a central clearance house on the OARSI website to
allow an overview of current available studies and data, for
example upcoming GWAS of the National Institutes of Health
sponsored OA Initiative (OAI) biospecimens (http://oai.epi-ucsf.org/
datarelease/). This clearance house will provide an overview on
available cohorts and thereby encourage collaboration so cohorts
can be used in different settings.
In addition, the Global Initiativewill identify parameters in areas
of common phenotypes, such as OA in multiple joints, and varying
age groups. Diverse phenotypes will likely require equally diverse
biomarkers for susceptibility, severity, and progression in combi-
nation with imaging approaches. Such an approach will help iden-
tify and follow OA, beginning with the earliest molecular changes.
The third and ﬁnal biomarkers workshopwill take place in 2012,
led by Professor David Hunter. This meeting will focus on imagingbiomarkers. Like the second meeting, the ﬁnal workshop will also
try and weave in what we have learnt from previous meetings to
create an overall view of the current state of art of OA biomarkers. It
will be of interest to know whether our understanding of the
genetic, epigenetic, and genomic basis of OA has substantially
progressed and whether it can integrate with conventional and
imaging biomarkers to enhance our ability to improve clinical
treatment of OA patients.
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